Variant Bio at ASHG 2026

Oct 20–24, 2026 Montréal, Canada ~7.5k attendees Website

Variant Bio at ASHG 2026 in Montréal: 1 presentation (1 poster).

Organization	ASHG 2026 Attendance
Variant Bio Seattle, Washington	1 Scientist
variantbio.com\|LinkedIn Private company~40 people Variant Bio develops human-genetics-informed therapeutics for pharmaceutical partners. Its Inference platform uses genomic and multi-omic data to identify drug targets. Appointed Craig Basson to advance its genomics-driven clinical programs, adding clinical-development leadership as it moves toward the clinic. › Appointed Craig Basson to advance its genomics-driven clinical programs, adding clinical-development leadership as it moves toward the clinic. 2026-01 · source Signed a target-discovery collaboration with Boehringer Ingelheim for kidney disease, a pharma partnership funding its human-genetics research. 2026-01 · source Launched Inference, an agentic AI platform for genomic drug-target discovery, a new tool it says is the first of its kind. 2026-01 · source Source: company newsroom Has raised $130M to date; latest round undisclosed › The company did not disclose its most recent funding round's size or investors. “The company has raised $130mm to date” Source: funding announcement Currently hiring: 2 open roles › Source: careers page	Poster Fri Oct 23 2:30 pm Part of Genetic Counseling, ELSI, and Education Poster Friday Session What Research Owes Participants: Long-Term Benefit Sharing as a Foundation for Ethical Genomics Exhibit & Poster Hall · Board 8013F Ethical, legal, and social implicationsGenomics

Organization

ASHG 2026 Attendance

Variant Bio

Seattle, Washington

1 Scientist

variantbio.com|LinkedIn

Private company~40 people

Variant Bio develops human-genetics-informed therapeutics for pharmaceutical partners. Its Inference platform uses genomic and multi-omic data to identify drug targets.

Appointed Craig Basson to advance its genomics-driven clinical programs, adding clinical-development leadership as it moves toward the clinic.

›

Appointed Craig Basson to advance its genomics-driven clinical programs, adding clinical-development leadership as it moves toward the clinic.

2026-01 · source

Signed a target-discovery collaboration with Boehringer Ingelheim for kidney disease, a pharma partnership funding its human-genetics research.

2026-01 · source

Launched Inference, an agentic AI platform for genomic drug-target discovery, a new tool it says is the first of its kind.

2026-01 · source

Source: company newsroom

Has raised $130M to date; latest round undisclosed

›

The company did not disclose its most recent funding round's size or investors.

“The company has raised $130mm to date”

Source: funding announcement

Currently hiring: 2 open roles

›

Source: careers page

Poster

Fri Oct 23
2:30 pm

Part of Genetic Counseling, ELSI, and Education Poster Friday Session

What Research Owes Participants: Long-Term Benefit Sharing as a Foundation for Ethical Genomics

Exhibit & Poster Hall · Board 8013F

Ethical, legal, and social implicationsGenomics

Instantly find 20 buyers from Variant Bio

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the American Society of Human Genetics. Submit a correction